Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCA036978 in Myeloproliferative Neoplasms
NCT07441694Phase 1Recruiting
- Sponsor
- Incyte
- Start
- May 2026
- Primary completion
- May 2030
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 1, open-label trial of INCA036978 in Myeloproliferative Neoplasm (MPN) (4 arms), sponsored by Incyte. Primary endpoints: Dose Limiting Toxicities at 28 days, Treatment-emergent Adverse Events at 2 years and 1 more. Started May 2026; status: recruiting.
02
Drugs
INCA036978
03
Conditions
Myeloproliferative Neoplasm (MPN)
Beyond the preview
Go deeper on NCT07441694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07441694.